Last Updated : November 6, 2024
Details
FilesGeneric Name:
everolimus
Project Status:
Active
Therapeutic Area:
Tuberous Sclerosis Complex (TSC)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0836-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC).
| Call for patient input open | December 14, 2023 |
|---|---|
| Call for patient/clinician input open | December 14, 2023 |
| Call for patient input closed | February 12, 2024 |
| Call for patient/clinician input closed | February 12, 2024 |
| Call for industry input open | December 14, 2023 |
| Call for industry input closed | February 12, 2024 |
| Submission received | December 12, 2023 |
| Review initiated | December 13, 2023 |
| Expert committee meeting (initial) | September 19, 2024 |
| Draft recommendation posted for stakeholder feedback | October 17, 2024 |
| End of feedback period | October 31, 2024 |
| Final recommendation posted | - |
| CADTH review report(s) posted | - |
Files
Last Updated : November 6, 2024